Literature DB >> 15592469

Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib.

Murat Bastepe1, Leopold F Fröhlich, Agnès Linglart, Hilal S Abu-Zahra, Katsuyoshi Tojo, Leanne M Ward, Harald Jüppner.   

Abstract

Epigenetic defects in the imprinted GNAS cluster are associated with pseudohypoparathyroidism type Ib. In two kindreds with this disorder, we now report deletions that remove the differentially methylated region encompassing exon NESP55 and exons 3 and 4 of the antisense transcript. When inherited from a female, either deletion abolishes all maternal GNAS imprints and derepresses maternally silenced transcripts, suggesting that the deleted region contains a cis-acting element that controls imprinting of the maternal GNAS allele.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592469     DOI: 10.1038/ng1487

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  71 in total

1.  Recessive versus imprinted disorder: consanguinity can impede establishing the diagnosis of autosomal dominant pseudohypoparathyroidism type Ib.

Authors:  Serap Turan; Leyla Akin; Teoman Akcay; Erdal Adal; Sevil Sarikaya; Murat Bastepe; Harald Jüppner
Journal:  Eur J Endocrinol       Date:  2010-06-10       Impact factor: 6.664

2.  Analysis of Multiple Families With Single Individuals Affected by Pseudohypoparathyroidism Type Ib (PHP1B) Reveals Only One Novel Maternally Inherited GNAS Deletion.

Authors:  Rieko Takatani; Angelo Molinaro; Giedre Grigelioniene; Olta Tafaj; Tomoyuki Watanabe; Monica Reyes; Amita Sharma; Vibha Singhal; F Lucy Raymond; Agnès Linglart; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

3.  A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gsα Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B).

Authors:  Giedre Grigelioniene; Pasi I Nevalainen; Monica Reyes; Susanne Thiele; Olta Tafaj; Angelo Molinaro; Rieko Takatani; Marja Ala-Houhala; Daniel Nilsson; Jesper Eisfeldt; Anna Lindstrand; Marie-Laure Kottler; Outi Mäkitie; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2017-02-24       Impact factor: 6.741

4.  A novel deletion involving GNAS exon 1 causes PHP1A and further refines the region required for normal methylation at exon A/B.

Authors:  Monica Reyes; Anara Karaca; Murat Bastepe; Nese Ersoz Gulcelik; Harald Jüppner
Journal:  Bone       Date:  2017-07-12       Impact factor: 4.398

5.  Madelung-like deformity in pseudohypoparathyroidism type 1b.

Authors:  Janine Sanchez; Erasmo Perera; Suzanne Jan de Beur; Changlin Ding; Anna Dang; Gary D Berkovitz; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2011-07-13       Impact factor: 5.958

Review 6.  The silence RNA keeps: cis mechanisms of RNA mediated epigenetic silencing in mammals.

Authors:  Cristina Tufarelli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

Review 7.  Imprinted noncoding RNAs.

Authors:  Jo Peters; Joan E Robson
Journal:  Mamm Genome       Date:  2008-09-25       Impact factor: 2.957

Review 8.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

Review 9.  Epigenetics and obesity.

Authors:  Reinhard Stöger
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B.

Authors:  Eduardo Fernandez-Rebollo; Beatriz García-Cuartero; Intza Garin; Cristina Largo; Francisco Martínez; Concepcion Garcia-Lacalle; Luis Castaño; Murat Bastepe; Guiomar Pérez de Nanclares
Journal:  J Clin Endocrinol Metab       Date:  2009-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.